NRG1

Cholangiocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID5858

In a single patient with presumed cholangiocarcinoma a novel ATP1B1-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the gene fusi… (full text at CIViC)

PMID 28950338 · Jones et al., 2017 · Open in CIViC

NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7492 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

NRG1 Fusion + KRAS WildtypeNRG1 KRAS1

Pancreatic Ductal Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID7492

Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC)

PMID 31068372 · Jones et al., 2019 · Open in CIViC

NRG1 Fusion2
Afatinib	Mucinous Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7490 A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC	civic
〃	Mucinous Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7494 A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC) PMID 29169524 · Cheema et al., 2017 · Open in CIViC	civic

NRG1 Fusion2

Predictive

Supports Sensitivity Response

submitted

EID7490

A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

〃

Predictive

Supports Sensitivity Response

submitted

EID7494

A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC)

PMID 29169524 · Cheema et al., 2017 · Open in CIViC

NRG1 Expression9
Afatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID7653 In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC) PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC	civic
Anti-ErbB3 Monoclonal Antibody AV-203	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID861 This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response. PMID 25542901 · Meetze et al., 2015 · Open in CIViC	civic
Carboplatin + Cisplatin + Gemcitabine + PaclitaxelSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID779 In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decrea… (full text at CIViC) PMID 23390248 · Hegde et al., 2013 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	4	accepted	EID777 NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity. PMID 21900593 · Yonesaka et al., 2011 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	1	submitted	EID7654 In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC) PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC	civic
Lapatinib	Head and Neck Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID776 In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified… (full text at CIViC) PMID 21840482 · Wilson et al., 2011 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID1967 Reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment in breast cancer cell lines, This was associated with increased expression of NRG1 in cells treated with lapatinib. PMID 25691057 · Leung et al., 2015 · Open in CIViC	civic
Patritumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID813 In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictiv… (full text at CIViC) PMID 26137564 · Mendell et al., 2015 · Open in CIViC	civic
Seribantumab	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID778 An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vi… (full text at CIViC) PMID 20227043 · Sheng et al., 2010 · Open in CIViC	civic

NRG1 Expression9

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID7653

In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC)

PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC

Anti-ErbB3 Monoclonal Antibody AV-203

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID861

This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response.

PMID 25542901 · Meetze et al., 2015 · Open in CIViC

Carboplatin + Cisplatin + Gemcitabine + PaclitaxelSubstitutes

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID779

In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decrea… (full text at CIViC)

PMID 23390248 · Hegde et al., 2013 · Open in CIViC

Cetuximab

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Resistance

accepted

EID777

NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.

PMID 21900593 · Yonesaka et al., 2011 · Open in CIViC

Erlotinib + GefitinibSubstitutes

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

submitted

EID7654

PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC

Head and Neck Squamous Cell Carcinoma

Lapatinib

Predictive

Supports Sensitivity Response

accepted

EID776

In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified… (full text at CIViC)

PMID 21840482 · Wilson et al., 2011 · Open in CIViC

Malignant Breast Neoplasm

〃

Predictive

Supports Resistance

submitted

EID1967

Reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment in breast cancer cell lines, This was associated with increased expression of NRG1 in cells treated with lapatinib.

PMID 25691057 · Leung et al., 2015 · Open in CIViC

Patritumab

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID813

In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictiv… (full text at CIViC)

PMID 26137564 · Mendell et al., 2015 · Open in CIViC

Malignant Ovarian Neoplasm

Seribantumab

Predictive

Supports Sensitivity Response

accepted

EID778

An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vi… (full text at CIViC)

PMID 20227043 · Sheng et al., 2010 · Open in CIViC

NRG1 NRG1 FUSIONS1
Afatinib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	rejected	EID7467 Two patients with pancreatic adenocarcinoma harboring NRG1 gene fusions were treated with afatinib. Both of them showed a tumor response. PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

NRG1 NRG1 FUSIONS1

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

rejected

EID7467

Two patients with pancreatic adenocarcinoma harboring NRG1 gene fusions were treated with afatinib. Both of them showed a tumor response.

PMID 31068372 · Jones et al., 2019 · Open in CIViC

NRG1 Fusion1
Afatinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5859 In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizin… (full text at CIViC) PMID 28950338 · Jones et al., 2017 · Open in CIViC	civic

NRG1 Fusion1

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID5859

In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizin… (full text at CIViC)

PMID 28950338 · Jones et al., 2017 · Open in CIViC

NRG1 Fusion3
Afatinib	Mucinous Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	rejected	EID7489 A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7491 A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC	civic
Erlotinib + LumretuzumabCombination	Mucinous Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID7495 Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC) PMID 30268483 · Kim et al., 2018 · Open in CIViC	civic

NRG1 Fusion3

Predictive

Supports Sensitivity Response

rejected

EID7489

A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

〃

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID7491

PMID 28502724 · Gay et al., 2017 · Open in CIViC

Erlotinib + LumretuzumabCombination

Predictive

Supports Sensitivity Response

submitted

EID7495

Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC)

PMID 30268483 · Kim et al., 2018 · Open in CIViC

NRG1 Fusion + NRG1 Fusion1
(prognostic)	Mucinous Lung AdenocarcinomaUNRESOLVED	Prognostic	B	Supports Poor Outcome	3	accepted	EID5814 13 patients with invasive mucinous adenocarcinoma of the lung from a cohort of 59 were found to be SLC3A2-NRG1 fusion positive. Survival was assessed according to the presence of the NRG1 fusion, whic… (full text at CIViC) PMID 27626312 · Shin et al., 2016 · Open in CIViC	civic

NRG1 Fusion + NRG1 Fusion1

(prognostic)

Mucinous Lung AdenocarcinomaUNRESOLVED

Prognostic

Supports Poor Outcome

accepted

EID5814

13 patients with invasive mucinous adenocarcinoma of the lung from a cohort of 59 were found to be SLC3A2-NRG1 fusion positive. Survival was assessed according to the presence of the NRG1 fusion, whic… (full text at CIViC)

PMID 27626312 · Shin et al., 2016 · Open in CIViC

NRG1 Fusion6
Afatinib	Pancreatic Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID6273 In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC	civic
〃	Mucinous Lung AdenocarcinomaUNRESOLVED	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID6096 One patient with an NRG1-rearranged invasive mucinous adenocarcinomas (IMAs) of the lung had a response with an anti-ERBB3 monoclonal antibody (GSK2849330). No response was achieved with afatinib in f… (full text at CIViC) PMID 29610121 · Drilon et al., 2018 · Open in CIViC	civic
Anti-HER3 Monoclonal Antibody GSK2849330	Mucinous Lung AdenocarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	submitted	EID6095 One patient with an NRG1-rearranged invasive mucinous adenocarcinomas (IMAs) of the lung had a response with an anti-ERBB3 monoclonal antibody (GSK2849330). No response was achieved with afatinib in f… (full text at CIViC) PMID 29610121 · Drilon et al., 2018 · Open in CIViC	civic
Erlotinib + PertuzumabCombination	Pancreatic Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7534 In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC	civic
Zenocutuzumab-zbco	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12246 On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with advanced, unresectable, or metastatic non-small cell lun… (full text at CIViC) PMID 39908431 · Schram et al., 2025 · Open in CIViC	civic
〃	Pancreatic Adenocarcinoma	Predictive	A	Supports Sensitivity Response	4	accepted	EID12247 On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with advanced, unresectable, or metastatic non-small cell lun… (full text at CIViC) PMID 39908431 · Schram et al., 2025 · Open in CIViC	civic

NRG1 Fusion6

Pancreatic Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID6273

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

〃

Mucinous Lung AdenocarcinomaUNRESOLVED

Predictive

Does Not Support Sensitivity Response

accepted

EID6096

One patient with an NRG1-rearranged invasive mucinous adenocarcinomas (IMAs) of the lung had a response with an anti-ERBB3 monoclonal antibody (GSK2849330). No response was achieved with afatinib in f… (full text at CIViC)

PMID 29610121 · Drilon et al., 2018 · Open in CIViC

Anti-HER3 Monoclonal Antibody GSK2849330

Mucinous Lung AdenocarcinomaUNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID6095

PMID 29610121 · Drilon et al., 2018 · Open in CIViC

Pancreatic Adenocarcinoma

Erlotinib + PertuzumabCombination

Predictive

Supports Sensitivity Response

submitted

EID7534

PMID 29802158 · Heining et al., 2018 · Open in CIViC

Zenocutuzumab-zbco

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID12246

On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with advanced, unresectable, or metastatic non-small cell lun… (full text at CIViC)

PMID 39908431 · Schram et al., 2025 · Open in CIViC

Pancreatic Adenocarcinoma

〃

Predictive

Supports Sensitivity Response

accepted

EID12247

PMID 39908431 · Schram et al., 2025 · Open in CIViC